# Millennium Pharmaceuticals, Inc. clinical trials: 178 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 178 trials with Millennium Pharmaceuticals, Inc. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Millennium Pharmaceuticals, Inc.: 178 rows for $8.90, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/millennium-pharmaceuticals-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 178
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 178, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 2, 2020 | NCT04535557 | An Expanded Access Protocol for Mobocertinib in Refractory Non-small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor... | Millennium Pharmaceuticals, Inc. | Not applicable | Approved for marketing | Carcinoma, Non-Small-Cell Lung | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04535557) |
| July 2, 2020 | NCT04454918 | Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and... | Millennium Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteers | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04454918) |
| October 9, 2019 | NCT04121078 | A Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototypic Inhibitor of Organic Anion Transporting Polypeptide... | Millennium Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteers | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04121078) |
| September 16, 2019 | NCT04091438 | A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia | Millennium Pharmaceuticals, Inc. | Phase 1 | Completed | Idiopathic Hypersomnia | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04091438) |
| September 16, 2019 | NCT04091425 | Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite... | Millennium Pharmaceuticals, Inc. | Phase 1 | Completed | Obstructive Sleep Apnea | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04091425) |
| August 14, 2019 | NCT04056468 | A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI)... | Millennium Pharmaceuticals, Inc. | Phase 1 | Completed | Hepatic Impairment, Healthy Volunteers | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04056468) |
| August 14, 2019 | NCT04056455 | A Study of Mobocertinib Capsules in People With Severe Kidney Problems and People With Healthy Kidneys | Millennium Pharmaceuticals, Inc. | Phase 1 | Completed | Renal Impairment, Healthy Volunteers | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04056455) |
| August 9, 2019 | NCT04051827 | Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) | Millennium Pharmaceuticals, Inc. | Phase 1 | Completed | Carcinoma, Non-Small-Cell Lung, Lung Neoplasms | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04051827) |
| June 19, 2019 | NCT03990649 | Study of TAK-935 as an Adjunctive Therapy in Adult Participants With Complex Regional Pain Syndrome (CRPS) | Millennium Pharmaceuticals, Inc. | Phase 2 | Completed | Complex Regional Pain Syndrome | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03990649) |
| April 26, 2019 | NCT03928327 | A Study to Evaluate Drug-Drug Interaction of TAK-788 With Itraconazole and Rifampin in Healthy Adult Participants | Millennium Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteers | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03928327) |
| March 25, 2019 | NCT03888534 | Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma... | Millennium Pharmaceuticals, Inc. | Phase 1 | Withdrawn | Precursor Cell Lymphoblastic Leukemia-lymphoma | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03888534) |
| March 12, 2019 | NCT03870555 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-954 in Healthy Adult Participants | Millennium Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteers | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03870555) |
| February 21, 2019 | NCT03849690 | A Trial to Evaluate the Effect of the Proton Pump Inhibitor Esomeprazole on the Single-dose Pharmacokinetics (PK) of Oral TAK-906 in... | Millennium Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteers | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03849690) |
| January 22, 2019 | NCT03811834 | A Study to Assess Absolute Bioavailability (ABA) of Mobocertinib (TAK-788) and to Characterize Mass Balance, Pharmacokinetics (PK)... | Millennium Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteers | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03811834) |
| November 21, 2018 | NCT03748953 | Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With... | Millennium Pharmaceuticals, Inc. | Phase 3 | Completed | Multiple Myeloma | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03748953) |
| October 30, 2018 | NCT03724916 | A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy... | Millennium Pharmaceuticals, Inc. | Phase 1 | Completed | Systemic Lupus Erythematosus, Lupus Erythematosus, Systemic | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03724916) |
| October 17, 2018 | NCT03708211 | A Study to Assess the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics... | Millennium Pharmaceuticals, Inc. | Phase 1 | Completed | Neoplasms, Advanced Solid | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03708211) |
| October 10, 2018 | NCT03701555 | A Study of PVP001, PVP002, and PVP003 in Healthy Adults and PVP001 and PVP002 in Adults With Celiac Disease | Millennium Pharmaceuticals, Inc. | Phase 1 | Completed | Digestive System Disease | 139 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03701555) |
| September 4, 2018 | NCT03657160 | Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic... | Millennium Pharmaceuticals, Inc. | Phase 3 | Completed | Hematopoietic Stem Cells | 343 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03657160) |
| June 1, 2018 | NCT03544229 | A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis | Millennium Pharmaceuticals, Inc. | Phase 2 | Completed | Diabetic Gastroparesis, Idiopathic Gastroparesis | 242 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03544229) |
| April 18, 2018 | NCT03501069 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Oral Dose of TAK-418... | Millennium Pharmaceuticals, Inc. | Phase 1 | Terminated | Healthy Volunteers | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03501069) |
| April 18, 2018 | NCT03500224 | A Study to Evaluate the Mass Balance, Pharmacokinetics (PK), Metabolism and Excretion of TAK-954 Containing Microtracer (\[14C\]-TAK-954) in... | Millennium Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteers | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03500224) |
| April 3, 2018 | NCT03486314 | A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors | Millennium Pharmaceuticals, Inc. | Phase 1 | Completed | Advanced Solid Neoplasm | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03486314) |
| March 29, 2018 | NCT03482453 | A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-788 Followed by Evaluation of the Effects of a Low-Fat Meal... | Millennium Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteers | 69 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03482453) |
| March 27, 2018 | NCT03477903 | TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI) | Millennium Pharmaceuticals, Inc. | Phase 2 | Terminated | Critical Illness, Enteral Nutrition, Enteral Feeding Intolerance | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03477903) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 93 |
| Phase 1/2 | 17 |
| Phase 2 | 43 |
| Phase 3 | 19 |
| Phase 4 | 2 |
| Not applicable | 2 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 147 |
| Terminated | 23 |
| Withdrawn | 6 |
| Approved for marketing | 1 |
| No longer available | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Multiple Myeloma | 26 |
| Lymphoma | 16 |
| Prostatic Neoplasms | 14 |
| Leukemia, Myeloid, Acute | 9 |
| Neoplasms | 9 |
| Recurrence | 8 |
| Carcinoma, Non-Small-Cell Lung | 8 |
| Lymphoma, Large B-Cell, Diffuse | 6 |
| Myelodysplastic Syndromes | 5 |
| Lymphoma, Non-Hodgkin | 5 |
| Lymphoma, Follicular | 5 |
| Hodgkin Disease | 4 |
| Ovarian Neoplasms | 4 |
| Crohn Disease | 4 |
| Lymphoma, Mantle-Cell | 4 |
| Lymphoma, Large-Cell, Anaplastic | 3 |
| Colitis, Ulcerative | 3 |
| Small Cell Lung Carcinoma | 3 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 |
| Hematologic Neoplasms | 3 |
| Breast Neoplasms | 3 |
| Waldenstrom Macroglobulinemia | 3 |
| Melanoma | 3 |
| Lymphoma, B-Cell | 3 |
| Neoplasm Metastasis | 3 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Chicken restaurants in the United States](https://specstream.ai/data/businesses/chicken-restaurants/united-states)
- [HVAC contractors in the United States](https://specstream.ai/data/businesses/hvac-contractors/united-states)
- [Public relations firms in the United States](https://specstream.ai/data/businesses/public-relations-firms/united-states)
- [Art schools in the United States](https://specstream.ai/data/businesses/art-schools/united-states)
- [Empanada restaurants in the United States](https://specstream.ai/data/businesses/empanada-restaurants/united-states)
